{"disease":{"id":"thrombocythemia","name":"thrombocythemia"},"drugs":{"marketed":[{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Essential thrombocythemia (ET) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Essential Thrombocythemia (ET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"anagrelide","indication_name":"Essential thrombocythemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agrylin","generic_name":"ANAGRELIDE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"cGMP-inhibited 3',5'-cyclic phosphodiesterase A","drug_class":"Platelet-reducing Agent","quality_score":10,"revenue":null,"mechanism":"Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count."}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Polycythemia vera and essential thrombocythemia (thromboembolism prevention)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."},{"drug_id":"hydroxyurea","indication_name":"Essential thrombocythemia","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":14,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT00567502","title":"Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":3647,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03745378","title":"Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1881,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT03625895","title":"Agrylin Drug Use-Result Survey","phase":"","overall_status":"COMPLETED","enrollment_count":1826,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05198960","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1308,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05044026","title":"A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":1012,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02897297","title":"Myeloproliferative Neoplastic Diseases Observatory From Brest","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07203768","title":"A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":678,"lead_sponsor_name":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","has_results":false},{"nct_id":"NCT06599385","title":"Platelet Transfusion in Critically Ill Patients With Thrombocytopenia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":536,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07357727","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01969838","title":"Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":432,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04603495","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03165734","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":407,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT06351631","title":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03662126","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06079879","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06456346","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04942080","title":"Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04551066","title":"To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":252,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04173494","title":"A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":195,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04551053","title":"To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01192347","title":"French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia","phase":"","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04285086","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT04884191","title":"Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"CTI BioPharma","has_results":true},{"nct_id":"NCT02101268","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT00202644","title":"A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02823184","title":"Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT06073847","title":"A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis","phase":"","overall_status":"RECRUITING","enrollment_count":137,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03869476","title":"Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.","phase":"NA","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT01981850","title":"A Phase 2 Study of RO7490677 In Participants With Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT01787487","title":"Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01392443","title":"Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06378437","title":"A Study of GLB-001 in Patients With Myeloid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Hangzhou GluBio Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01520220","title":"Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT05482971","title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":91,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT03136185","title":"Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02124746","title":"Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT04455841","title":"INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT05223920","title":"An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06343805","title":"A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ajax Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04254978","title":"Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT00946270","title":"Pomalidomide for Myelofibrosis Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03232177","title":"Anagre Cap. in Patients With High-Risk Essential Thrombocythemia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT06361641","title":"Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT06661915","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01433445","title":"Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01198717","title":"Pediatric Disease Registry in Essential Thrombocythaemia (ET)","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Shire","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}